Signaturefd LLC Has $2.03 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Signaturefd LLC cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,049 shares of the pharmaceutical company’s stock after selling 100 shares during the period. Signaturefd LLC’s holdings in Vertex Pharmaceuticals were worth $2,033,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. OneDigital Investment Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 62.7% during the third quarter. OneDigital Investment Advisors LLC now owns 2,817 shares of the pharmaceutical company’s stock worth $1,310,000 after purchasing an additional 1,086 shares during the last quarter. Claro Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 24.1% during the 3rd quarter. Claro Advisors LLC now owns 2,425 shares of the pharmaceutical company’s stock worth $1,128,000 after buying an additional 471 shares during the last quarter. Quest Partners LLC grew its position in shares of Vertex Pharmaceuticals by 3,856.6% in the third quarter. Quest Partners LLC now owns 3,284 shares of the pharmaceutical company’s stock valued at $1,527,000 after purchasing an additional 3,201 shares during the last quarter. Meeder Advisory Services Inc. grew its holdings in Vertex Pharmaceuticals by 1.1% in the 3rd quarter. Meeder Advisory Services Inc. now owns 5,634 shares of the pharmaceutical company’s stock valued at $2,620,000 after buying an additional 62 shares in the last quarter. Finally, Joseph Group Capital Management increased its position in Vertex Pharmaceuticals by 17.7% during the third quarter. Joseph Group Capital Management now owns 5,672 shares of the pharmaceutical company’s stock worth $2,638,000 after acquiring an additional 855 shares during the period. 90.96% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Ourania Tatsis sold 244 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now directly owns 67,695 shares in the company, valued at $30,805,286.70. This represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,315 shares of company stock worth $2,121,012. Insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and upped their price objective for the stock from $408.00 to $424.00 in a research report on Tuesday, February 11th. JPMorgan Chase & Co. lowered their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a report on Monday, December 23rd. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 11th. Royal Bank of Canada upped their target price on Vertex Pharmaceuticals from $407.00 to $408.00 and gave the company a “sector perform” rating in a report on Thursday, February 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Ten analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $506.70.

Vertex Pharmaceuticals Trading Up 1.8 %

Shares of VRTX opened at $513.76 on Tuesday. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company’s fifty day simple moving average is $459.97 and its 200-day simple moving average is $461.84. The company has a market cap of $131.93 billion, a P/E ratio of -233.53, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.